Drug Profile

VC 005

Alternative Names: VC-005

Latest Information Update: 19 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Vcare Pharmatech
Class Anti-inflammatories; Antirheumatics; Skin disorder therapies
Mechanism of Action Janus kinase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Atopic dermatitis
Phase II Ankylosing spondylitis
Phase I Rheumatoid arthritis
No development reported Inflammatory bowel diseases

Most Recent Events

15 Sep 2025 Jiangsu vcare pharmaceutical technology plans to initiate a phase III trial for Ankylosing Spondylitis in China (PO) (NCT07172360)
15 Sep 2025 Jiangsu Vcare Pharmatech plans a phase II trial for Vitiligo in China (PO, Tablet), in October 2025 (NCT07172347)
15 Aug 2025 VC 005 is licensed to Huadong Medicine in China

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com